Cargando…

Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin

Insulin-dependent diabetic patients have to count on the administration of painful and discomforting insulin injections. However, inadequate insulin absorption and the risk of insulin level escalation in the blood are some disadvantages associated with insulin therapy. Thus, the current study intend...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathore, Priyanka, Mahor, Alok, Jain, Surendra, Haque, Anzarul, Kesharwani, Prashant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058365/
https://www.ncbi.nlm.nih.gov/pubmed/35519724
http://dx.doi.org/10.1039/d0ra07640f
_version_ 1784698099184173056
author Rathore, Priyanka
Mahor, Alok
Jain, Surendra
Haque, Anzarul
Kesharwani, Prashant
author_facet Rathore, Priyanka
Mahor, Alok
Jain, Surendra
Haque, Anzarul
Kesharwani, Prashant
author_sort Rathore, Priyanka
collection PubMed
description Insulin-dependent diabetic patients have to count on the administration of painful and discomforting insulin injections. However, inadequate insulin absorption and the risk of insulin level escalation in the blood are some disadvantages associated with insulin therapy. Thus, the current study intends to formulate insulin-loaded chitosan nanoparticles for refining the systemic absorption of insulin via the ocular route. Insulin-loaded chitosan nanoparticles were prepared by the ionotropic gelation method and characterized for various parameters. Optimized insulin loaded nanoparticles (C4T4I4) were positively charged with a particle size of 215 ± 2.5 nm and showed 65.89 ± 4.3% entrapment efficiency. The in vitro drug release exhibited sustained release of insulin, where 77.2 ± 2.1% of release was observed after 12 h and leads to an assumption of the non-Fickian diffusion release mechanism. The permeation study discloses good mucoadhesive and better permeation properties of insulin loaded nanoparticles compared to free Insulin. No significant difference was observed in the size of particles after six months of storage, signifying their adequate stability. Nanoparticles were found to be non-irritant to ocular tissues and exhibited prominent blood glucose level reduction in vivo. The outcomes of this study suggested that the chitosan nanoparticulate system could act as a prominent carrier system for insulin with enhanced stability and efficacy.
format Online
Article
Text
id pubmed-9058365
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90583652022-05-04 Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin Rathore, Priyanka Mahor, Alok Jain, Surendra Haque, Anzarul Kesharwani, Prashant RSC Adv Chemistry Insulin-dependent diabetic patients have to count on the administration of painful and discomforting insulin injections. However, inadequate insulin absorption and the risk of insulin level escalation in the blood are some disadvantages associated with insulin therapy. Thus, the current study intends to formulate insulin-loaded chitosan nanoparticles for refining the systemic absorption of insulin via the ocular route. Insulin-loaded chitosan nanoparticles were prepared by the ionotropic gelation method and characterized for various parameters. Optimized insulin loaded nanoparticles (C4T4I4) were positively charged with a particle size of 215 ± 2.5 nm and showed 65.89 ± 4.3% entrapment efficiency. The in vitro drug release exhibited sustained release of insulin, where 77.2 ± 2.1% of release was observed after 12 h and leads to an assumption of the non-Fickian diffusion release mechanism. The permeation study discloses good mucoadhesive and better permeation properties of insulin loaded nanoparticles compared to free Insulin. No significant difference was observed in the size of particles after six months of storage, signifying their adequate stability. Nanoparticles were found to be non-irritant to ocular tissues and exhibited prominent blood glucose level reduction in vivo. The outcomes of this study suggested that the chitosan nanoparticulate system could act as a prominent carrier system for insulin with enhanced stability and efficacy. The Royal Society of Chemistry 2020-12-08 /pmc/articles/PMC9058365/ /pubmed/35519724 http://dx.doi.org/10.1039/d0ra07640f Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Rathore, Priyanka
Mahor, Alok
Jain, Surendra
Haque, Anzarul
Kesharwani, Prashant
Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
title Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
title_full Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
title_fullStr Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
title_full_unstemmed Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
title_short Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
title_sort formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058365/
https://www.ncbi.nlm.nih.gov/pubmed/35519724
http://dx.doi.org/10.1039/d0ra07640f
work_keys_str_mv AT rathorepriyanka formulationdevelopmentinvitroandinvivoevaluationofchitosanengineerednanoparticlesforoculardeliveryofinsulin
AT mahoralok formulationdevelopmentinvitroandinvivoevaluationofchitosanengineerednanoparticlesforoculardeliveryofinsulin
AT jainsurendra formulationdevelopmentinvitroandinvivoevaluationofchitosanengineerednanoparticlesforoculardeliveryofinsulin
AT haqueanzarul formulationdevelopmentinvitroandinvivoevaluationofchitosanengineerednanoparticlesforoculardeliveryofinsulin
AT kesharwaniprashant formulationdevelopmentinvitroandinvivoevaluationofchitosanengineerednanoparticlesforoculardeliveryofinsulin